◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

M3, Inc. (2413)

Name: M3, Inc.（2413）— 财务报表历史
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

来自官方财务报表的收入、利润与现金流历史。

Healthcare · 华尔街（美国） · 最近更新： 2026-09-20

M3, Inc. provides medical-related services to physicians and other healthcare professionals through the internet. It operates m3.com, a members-only website for providing information, tools, and services for medical professionals; MR-kun which delivers the latest medical information for daily medical practice; QOL-kun, a marketing support service that provides selected information useful for doctors; m3.com CAREER, a physician recruitment and career change support site; and Yakucari, a job search website for pharmacists.

关键数据

市值: JPY 1.18 trillion
收入（截至 2026-03-31 财年）: JPY 351.4B
净利润: JPY 49.1B
毛利率: 50.0%
净利率: 14.0%

查看交互式图表与完整报表 → 估值模型 (DCF) →

年度利润表

利润表	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
总收入	JPY 351.4B	JPY 284.9B	JPY 238.9B	JPY 230.8B	—
毛利	JPY 175.8B	JPY 154.4B	JPY 140.5B	JPY 135.2B	—
营业利润（EBIT）	JPY 71.1B	JPY 60.3B	JPY 63.0B	JPY 70.5B	—
净利	JPY 49.1B	JPY 40.5B	JPY 45.3B	JPY 49.0B	—

来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。

资产负债表、现金流、季度数据与完整财务比率见 2413 交互式查看器。 /companies/us/2413

类似公司

本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。

English version →全部股票

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.